StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Equities researchers at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $0.70 on Wednesday. The firm has a 50 day moving average price of $2.01 and a 200-day moving average price of $3.72. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $9.35.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Headlands Technologies LLC raised its position in shares of Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 2,861 shares in the last quarter. Creative Planning bought a new position in Eagle Pharmaceuticals in the third quarter valued at $59,000. Mackenzie Financial Corp purchased a new stake in Eagle Pharmaceuticals during the second quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth about $65,000. Finally, Fidelis Capital Partners LLC purchased a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth about $71,000. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.